Tedros Adhanom Ghebreyesus Spain South Africa covid-19 Health Manufacturing Tedros Adhanom Ghebreyesus Spain South Africa

New agreement under C-TAP aims to improve global access to COVID-19 testing technologies

Reading now: 841
www.who.int

A new, open, transparent sublicence agreement between the Medicines Patent Pool (MPP) on behalf of C-TAP, and South African pharmaceutical company Biotech Africa will accelerate the manufacture and sale of a COVID-19 serological antibody technology around the world.

The World Health Organization welcomes the sublicence agreement, the first of its kind to be signed under the auspices of the WHO’s COVID-19 Technology Access Pool (C-TAP) initiative.

C-TAP was set up in 2020 to facilitate the timely, equitable and affordable access to COVID-19 health products.The new agreement builds on a licensing agreement announced by WHO and MPP last year with Spain’s National Research Council (CSIC).

The non-exclusive sublicence allows Biotech to manufacture and commercialize CSIC’s COVID-19 serological test worldwide.“The most effective way to get – and keep – ahead of COVID-19 is to keep testing,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This new agreement means we can take advantage of untapped manufacturing capacity so more people in more countries can have easier access to affordable diagnostics.”The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine.

Read more on who.int
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

Waterloo Region expecting first doses of pediatric COVID-19 vaccine by end of July - globalnews.ca - Canada - county Ontario
globalnews.ca
50%
280
Waterloo Region expecting first doses of pediatric COVID-19 vaccine by end of July
Waterloo Public Health is expecting to get its first doses of Moderna’s two-dose pediatric COVID-19 vaccine for children aged six months to five years of age by the end of the month.“At this time, we are awaiting more direction from the Province,” a spokesperson told Global News in an email.“We expect to receive shipments of the Moderna vaccine towards the end of July for this age group.” COVID outbreaks more than doubled in Ontario LTC homes since last weekly report On Thursday, Health Canada announced that Moderna’s two-dose pediatric vaccine for young children had given the green light.The region says it expected approval to arrive at some point and had been planning for the rollout of the vaccine for the only remaining age group not yet offered COVID immunizations.“Pharmacies will continue to administer vaccines, and given the age of the youngest children, primary care providers will have an important role,” the spokesperson said.Earlier this week, the province announced that most people over the age of 18 would now be eligible for a fourth dose of COVID-19. Ontario to receive pediatric COVID-19 vaccine next week Within hours, the region announced that area residents would be able to get doses at family doctors, pharmacies and its clinics.Those using the region’s clinics would need to use the province’s booking system, which is the first time this would be the case.
DMCA